{"prompt": "['75', 'MC1488 WEE1', 'MCCC', 'Sekulic A, Migden MR, Oro AE, Efficacy and safety of vismodegib in advanced basal-cell', 'carcinoma. 2012 Jun 7;366(23):2171-9.', 'Telfer NR, Colver GB, Morton CA (2008). Guidelines for the management of basal cell carcinoma. Br J', 'Dermatol ;159(1):35-48.', 'Tibes R, Mesa RA. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the', 'impact of JAK2 inhibitor therapy? Leuk Lymphoma. 2011 Jul;52(7):1178-87.', 'Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME, Gonzales IM, Demuth T,', 'Slack J, Mesa RA, Braggio E, Yin HH, Arora S, Azorsa DO. RNAi screening of the kinome with', 'cytarabine in leukemias. Blood. 2012 Mar 22;119(12):2863-72.', 'Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S,', 'Berenzon D, Powell BL, Pardee T. Efficacy of the hypomethylating agents as frontline, salvage,', 'or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014', 'Jan;93(1):47-55.', 'University of Washington, Department of Pharmaceutics (2008). Metabolism and Transport Drug', 'Interaction Database, Version 4.0 (Internet) Available from:', '(http://www.druginteractioninfo.org> (Accessed 30 Nov 2010)', 'US Department of Health and Human Services (2007) Guidance for Industry Clinical Trial Enppoints for', 'the Approval of Cancer Drugs and Biologics. FDA', 'Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC. Inhibition of', 'Weel sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo,', 'independent of p53 functionality. Mol Cancer Ther. 2013 Dec;12(12):2675-84.', 'Vantuchova Y, Curik R (2006). Histological types of basal cell carcinoma. Scripta Medica (BRNO) ;', '78:261-70', 'Visani G, Malagola M, Piccaluga PP, Isidori A. Low dose Ara-C for myelodysplastic syndromes: is it still', 'a current therapy? Leuk Lymphoma. 2004 Aug;45(8):1531-8.', 'Von Hoff, D. D. et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N', 'Engl J Med 361, 1164-1172, (2009).', 'Wang, Y., McMahon, A. P. & Allen, B. L. Shifting paradigms in Hedgehog signaling. Curr Opin', 'Cell Biol 19, 159-165, (2007).', 'Weiss GJ, Tibes R et al. Long-Term Safety, Tolerability, and Efficacy of Vismodegib in Two', 'Patients with Metastatic Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Dermatology', 'Reports: 2011-12-01 10:05:25.', 'Wong C S M, Strange R C, Lear JT (2003) Basal Cell Carcinoma. BMJ; 327:794-798.', 'Zhao, C. et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid', 'leukaemia. Nature 458, 776-779, (2009).']['MC1488 WEE1', '76', 'MCCC']\n\n###\n\n", "completion": "END"}